New cell therapy aims to make risky transplants safer for blood cancer patients
NCT ID NCT06551584
Summary
This early-stage study is testing the safety of a new cell therapy called Orca-T for adults with advanced blood cancers like leukemia. The goal is to see if combining Orca-T with two standard medications can reduce serious complications after a stem cell transplant from a partially matched donor. Researchers will enroll up to 24 participants to closely monitor their health for the first 100 days after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.